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Non-Alcoholic Fatty Liver Disease (NAFLD) is now considered as the hepatic 
component of metabolic syndrome. Its prevalence, paralleling the growing diffusion of 
obesity and type II diabetes, is increasing worldwide both in adults and children. NAFLD is 
estimated to affect up to 30% of the general population in Western countries, reaching an 
even higher prevalence among diabetic and obese individuals [1,2]. From 20 to 30% of 
NAFLD patients are expected to develop non-alcoholic steatohepatitis (NASH), 
characterized by steatosis, parenchymal damage, lobular/portal inflammation with or 
without perisinusoidal and/or portal fibrosis. NASH can eventually progress to more severe 
fibrosis and cirrhosis [3], with development of hepatocellular carcinoma (HCC) detected in 
both cirrhotic and non-cirrhotic adults [4] and sometimes also in children/young adults [5].    
Notwithstanding the relevant clinical and social impact of NAFLD/NASH, the exact 
mechanisms responsible for NAFLD progression to more severe liver injury, in pediatric 
and adult individuals, remain elusive and we lack effective therapies and diagnostic tools 
to identify NAFLD patients at risk of progression. According to the hypothesis of multiple 
parallel hits, current literature indicates oxidative stress, inflammasome activation, 
lipotoxicity and changes in gut microbiota as most relevant mechanisms  [6].    
The involvement of oxidative stress, in particular, has been unequivocally 
documented in both pediatric and adult conditions of NAFLD, reproduced by experimental 
studies in rodents and suggested to favor NAFLD progression [7,8].  In experimental 
NAFLD oxidative stress can result from increased generation of reactive oxygen species 
(ROS) depending on several critical events, including impairment of mitochondria due to 
overload of free fatty acids (FFA), increased FFA metabolism in endoplasmic reticulum by 
cytochrome P450 isoforms 2E1 and 4A or in peroxisomes, lipotoxicity and endoplasmic 
reticulum stress, the presence of hypoxic conditions, as well as ROS generation through 
NADPH-oxidase isoforms associated to ligand-receptor interactions (growth factors, 
cytokines, chemokines, adipokines) or by activated inflammatory cells. Whatever the 
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source, ROS and oxidative stress are widely accepted to contribute to NAFLD progression 
by eliciting parenchymal death and by sustaining both inflammatory and fibrogenic 
responses [7,8].   
On this background, we find the results reported by Sundaram et al. in this issue of 
Journal of Hepatology [9] intriguing. They provide clinically sound data suggesting that 
nocturnal hypoxia (NH), associated with obesity-related obstructive sleep apnea (OSA), 
may promote the progression of pediatric NAFLD by significantly contributing to hepatic 
oxidative stress. According to current guidelines OSA is defined as a “disorder of breathing 
during sleep characterized by prolonged partial upper airway obstruction and/or 
intermittent complete obstruction (obstructive apnea) that disrupts normal ventilation 
during sleep and normal sleep patterns” [10]. Patients with OSA syndrome (OSAS), in 
particular, can experience repeated episodes of NH alternating with normoxia  (i.e., 
chronic intermittent hypoxia). This is accompanied by symptoms or signs that include 
habitual snoring (often with intermittent pauses, snorts, or gasps), disturbed sleep, and 
daytime neurobehavioral problems. Daytime sleepiness may occur, but is uncommon in 
young children. Pediatric OSA instead is also associated with neurocognitive impairment,  
behavioral problems, hypertension, cardiac dysfunction, and systemic inflammation [10]. 
Interestingly, in the present obesity epidemics, obese children represent a category of 
patients where those with OSA may reach a proportion of up to 36% [11]. 
Recent studies have reported a link not only between OSAS and cardiometabolic 
alterations, but also between OSAS and either direct (hepatic histology) or indirect (ALT or 
GGT levels) markers of liver damage in morbidly obese NAFLD adult and pediatric 
patients [reviewed in 12,13]. Two years ago the same group of Sundaram reported an 
alarming 60% OSA incidence in pediatric NAFLD. The severity/duration of hypoxiemia was 
associated with biochemical and histologic measures of NAFLD severity [14]. The same 
year Nobili et al. confirmed similar incidence and the presence and severity of OSAS 
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associated with the presence of NASH significant fibrosis, and NAFLD activity score 
independently of body mass index, abdominal adiposity, metabolic syndrome, and insulin 
resistance. This relationship held also in non-obese children with NAFLD and the duration 
of hemoglobin desaturation correlated with increased intrahepatic leukocytes and activated 
macrophages/Kupffer cells and with circulating markers of hepatocyte apoptosis and 
fibrogenesis [15]. The association OSA-NASH severity finally was found to correlate with 
increased endotoxemia coupled with impaired gut barrier function, leading to increased 
TLR-4-mediated hepatic susceptibility to endotoxemia [16], in keeping with the concept 
that gut microbiota plays a role in the development of hepatic steatosis and its progression 
to NASH [17]. 
The study by Sundaram and colleagues has addressed now NH as a potential source 
of oxidative stress in NAFLD [9]. Authors have studied 14 lean control adolescents and 36 
adolescents (25 with OSA/NH) with biopsy proven NAFLD,  polysomnographic 
characterization, liver histology scoring, and laboratory testing. Oxidative stress has been 
convincingly documented in this study by evaluating systemic (urine F2-isoprostanes] and 
hepatic (immunohistochemistry for 4-hydroxynonenal) reliable markers of “in vivo” lipid 
peroxidation [7,8].   
This study is particularly welcome because of conflicting results reported in literature, 
correctly quoted in the Sundaram et al. paper [9],  some reporting increased oxidative 
stress in adults with OSA as compared to healthy controls but others suggesting that 
oxidative stress in OSA patients was related to obesity rather than intermittent hypoxia. In 
their study, in addition to confirm the frequent association of OSA in pediatric NAFLD with 
deficiency of serum anti-oxidants, Authors call attention to a number of relevant points: i) 
NAFLD subjects with definite NASH (NAS histologic score > 5) had more severe sleep 
disordered breathing and significantly higher apnea/hypopnea index scores compared to 
those without definite NASH; ii) a correlation between the more severe fibrosis detected in 
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patients with OSA/hypoxia versus those without OSA/hypoxia; iii) a clear correlation 
between severity of the indexes of oxidative stress and the severity of the indexes used to 
evaluate OSA/NH; iv) the two populations of obese NAFLD adolescents did not differ for 
other relevant serum liver indexes and liver histology score (steatosis, ballooning 
degeneration, inflammation, NAS score). The suggestion is that obese NAFLD 
adolescents experiencing OSA/NH will then experience a surplus of hepatic oxidative 
stress that correlates with a more severe fibrosis than in non-OSA/NH NAFLD patients. 
This is reasonable since the repeated episodes of NH and normoxia (chronic intermittent 
hypoxia) in OSA/NH can easily lead to enhanced mitochondrial generation of ROS. 
Moreover, increased ROS generation in a hypoxic environment can sustain liver 
fibrogenesis through either ROS themselves or through responses operating through 
hypoxia-inducible factors (HIFs; i.e., known to be stabilized and then amplified by 
intracellular ROS) [7,8].  Although further studies designed to investigate specifically the 
role of HIFs are needed, both events have been suggested to modulate either the release 
of pro-inflammatory and pro-fibrogenic mediators by macrophages or activated hepatic 
stellate cells (HSCs) or by directly targeting HSCs. It should be noted, in particular, that the 
most relevant pro-fibrogenic phenotypical responses by activated HSCs are sustained by 
increased intracellular levels of ROS not able to induce cytotoxicity  [reviewed in ref. 8].  
Accordingly, this scenario closely resembles the described increase in liver injury and 
fibrosis reported in a rodent dietary model (high fat diet) of NAFLD/NASH when associated 
with chronic intermittent hypoxia [18]. 
However, like most investigations on this topic and as the Authors themselves 
acknowledge, this well-designed study is not exempt from some inevitable and evitable 
limitations. The major inevitable limitations are the poor generalizability (89% Hispanic 
subjects), the small sample size, the cross-sectional nature of the study not proving a 
causal link between OSA and liver damage, the possible bias towards a focus on more 
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severe liver disease due to enrollment of subjects who underwent liver biopsy for chronic 
elevation of aminotransferases, and the intrinsic ethics issues for the invasiveness of liver 
biopsy itself. Evitable limitations are the absence of a “healthy” obese control group and  
the lack of information about patients adiposity criteria other than BMI  (e.g., the waist-to-
height ratio, or WC cm > 95 %le  for age and gender [19].  For lean controls, a lesser 
disproportion of Hispanic subjects, polysomnography and liver ultrasounds data, and/or a 
specific validated OSA clinical score might have added weight to the Authors’ conclusions 
and possible insights into the bi-directionality of the events studied. 
In any case, the study by Sundaram et al. [9] has merit and outlines a number of 
further relevant issues and perspectives. The reported significant relationships between i) 
blood hematocrit (Hct) and NAFLD fibrosis stage and ii) anti-oxidant blood values, and 
NAFLD and lipid peroxidation parameters, may suggest that their combined evaluation 
should help in deciding whether histological ad polysomnographic evaluation are needed 
in order to early recognize subjects with more severe NAFLD and/or more severe OSA  
and hypoxia. Finally, since nocturnal Continuous Positive Airway Pressure (CPAP) is a 
treatment modality also for pediatric NAFLD patients with OSA/hypoxia, we definitively 
need trials designed to investigate whether CPAP treatment may significantly affect 
NAFLD progression in this age range. In fact at present the only randomized controlled 
trial on the possible efficacy of CPAP treatment was of relatively short duration, performed 
on adult patients with mild OSA/hypoxia and normal baseline transaminases, and 
apparently did not demonstrate any impact on steatosis, NASH or liver fibrosis, as 
evaluated by FibroMax score [20]. 
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